Purpose Salivary gland cancers (SGCs) are relatively rare but comprise various histologic subtypes, which complicates design of prospective trials. Systemic chemotherapy plays a limited role in treatment of SGCs, but cisplatin and docetaxel showed efficacy in a previous preclinical study. Here, we conduct a prospective, phase II study to evaluate the efficacy and toxicities of cisplatin plus weekly docetaxel in patients with metastatic or recurrent SGC.
Materials and Methods We included patients with histologically confirmed SGCs of the following subtypes: mucoepidermoid carcinoma, adenocarcinoma, ductal carcinoma, or adenoid cystic carcinoma. Patients had no prior systemic chemotherapy for metastatic or recurrent tumors and at least one measurable lesion. Patients were treated with docetaxel 35 mg/m2 (D1, 8) and cisplatin 70 mg/m2 (D1) every 21 days.
Results Forty-one patients were enrolled between April 2014 and October 2020. The median age was 58 years (range, 32 to 73 years). The most common histologic subtype was adenoid cystic carcinoma (63.4%), followed by ductal carcinoma (24.4%). The most common metastatic site was the lung (75.6%). The median treatment cycle was 5.5 (range, 3 to 8), and the objective response rate was 46.3%, with three complete responses. The median duration of response was 6.8 months (interquartile range, 4.0 to 10.2). The progression-free survival and overall survival were 9.4 months (95% confidence interval [CI], 8.4 to 10.5) and 28.2 months (95% CI, 22.7 to 33.6), respectively. There were no treatment-related deaths. The most common grade 3/4 adverse events were neutropenia (4.9%) and fatigue (4.9%).
Conclusion Cisplatin plus weekly docetaxel is effective and tolerable with manageable toxicity as first-line therapy in patients with metastatic or recurrent SGC.
Citations
Citations to this article as recorded by
Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review) Katarzyna Stawarz, Monika Durzynska, Adam Gałązka, Anna Gorzelnik, Jakub Zwolinski, Monika Paszkowska, Karolina Bieńkowska‑Pluta, Magdalena Misiak‑Galazka Oncology Letters.2025;[Epub] CrossRef
Clinical Course of Parotid Carcinoma with Hepatic and Nodal Metastases: A Case Report Antonio Doronzo, Giovanni Musci, Gennaro Gadaleta-Caldarola, Maria Chiara Sergi International Journal of Translational Medicine.2024; 5(1): 3. CrossRef
Systemic and Targeted Therapies in Adenoid Cystic Carcinoma Alec J. Kacew, Glenn J. Hanna Current Treatment Options in Oncology.2023; 24(1): 45. CrossRef
Major and minor salivary gland cancers: A multicenter retrospective study Muhammet Bekir Hacioglu, Bulent Erdogan, Murat Bardakcı, Efnan Algın, Burcu Gulbagcı, Ilhan Hacibekiroglu, Jamshid Hamdard, Omer Fatih Olmez, Hadi Akkus, Berna Oksuzoglu, Sema Sezgin Goksu, Shute Ailia Dae, Ahmet Taner Sumbul, Muzaffer Ugraklı, Mustafa Ka Head & Neck.2023; 45(7): 1643. CrossRef
Prognostic Significance of Primary Tumor Surgery in Adenoid Cystic Carcinoma Patients With Distant Metastases at Diagnosis: A Population-Based Database Analysis in Head and Neck Region Han Li, Li Zhao, Yixuan Song, Yang Liu, Song Ni, Shaoyan Liu Ear, Nose & Throat Journal.2023;[Epub] CrossRef
The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now? Robbert Cleymaet, Tijl Vermassen, Renaat Coopman, Hubert Vermeersch, Stijn De Keukeleire, Sylvie Rottey International Journal of Molecular Sciences.2022; 23(23): 14891. CrossRef
Joon Young Hur, Youjin Kim, Ghee-Young Kwon, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Su Jin Lee, Se Hoon Park
Cancer Res Treat. 2019;51(4):1269-1274. Published online January 9, 2019
Purpose
Treatment targeting immune checkpoint with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has demonstrated efficacy and tolerability in the treatment of metastatic urothelial carcinoma (mUC). We investigated the efficacy and safety of atezolizumab in mUC patients who failed platinum-based chemotherapy.
Materials and Methods
A retrospective study using the Samsung Medical Center cancer chemotherapy registry was performed on 50 consecutive patients with mUC treated with atezolizumab, regardless of their PD-L1(SP142) status, as salvage therapy after chemotherapy failure between May 2017 and June 2018. Endpoints included overall response rate (RR), progression-free survival (PFS), and safety.
Results
Among 50 patients, men constituted 76% and the median age was 68 years (range, 46 to 82 years). Twenty-three patients (46%) received atezolizumab as second-line therapy. PD-L1 (SP142) status IC0/1 and IC2/3 were found in 21 (42%) and 21 (42%) of patients, respectively; in eight patients (16%), PD-L1 (SP142) expression was not available. Atezolizumab was generally well tolerated, with pruritus and fatigue being the most commonly observed toxicities. As a result, partial response was noted in 20 patients (40%), with 12 (24%) stable diseases. RRwas higherin IC2/3 (62%) than in IC0/1 patients (24%, p=0.013). The median PFS was 7.4 months (95% confidence interval, 3.4 to 11.4 months). As expected, PFS also was significantly longer in IC2/3 patients than in IC0/1 (median, 12.7 vs. 2.1 months; p=0.005). PFS was not significantly influenced by age, sex, performance status, number of previous chemotherapy, site of metastases, or any of the baseline laboratory parameters.
Conclusion
In this retrospective study, atezolizumab demonstrated clinically efficacy and tolerability in unselected mUC patients who failed platinum-based chemotherapy.
Citations
Citations to this article as recorded by
Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer Rocío Díaz Acedo, Mercedes Galvan Banqueri, Silvia Artacho Criado, Eva María Fernández Parra, Rocío Jiménez Galán, Ana Isabel Gago Sánchez, Juan Francisco Marín Pozo, María José Martínez Bautista International Journal of Clinical Pharmacy.2024; 46(2): 382. CrossRef
Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma Joohyun Hong, Hyun Hwan Sung, Byong Chang Jeong, Se Hoon Park Biomedicines.2022; 10(8): 2005. CrossRef
Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options Inkeun Park, Jae Lyun Lee The Korean Journal of Internal Medicine.2020; 35(4): 834. CrossRef
Jeong Il Yu, Do Hoon Lim, Jeeyun Lee, Won Ki Kang, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Seung Tae Kim, Su Jin Lee, Sung Kim, Tae Sung Sohn, Jun Ho Lee, Ji Yeong An, Min Gew Choi, Jae Moon Bae, Heejin Yoo, Kyunga Kim
Cancer Res Treat. 2019;51(3):876-885. Published online October 1, 2018
Purpose
The purpose of this study was to compare prognostic differentiation performances of the 7th and the 8th edition of American Joint Commission on Cancer (AJCC) staging system for gastric cancer (GC) patients.
Materials and Methods
A total of 1,633 GC patients who underwent curative D2 resection followed by adjuvant chemotherapy alone (CA) or concurrent chemo-radiotherapy (CCRT) from 2004 to 2013 were included. Concordance index (c-index) was applied to compare the discriminatory ability.
Results
In the 8th edition, migration of stage was detected in 248 patients (15.2%). Among them, 121 patients were up-staged while 127 patients were down-staged. Overall, there was no statistically significant difference in the discriminatory ability between the 7th and 8th editions. The new edition of staging system, however, showed a trend of better prognostic performance not only in recurrence-free survival (c-index=0.734; 95% confidence interval [CI], 0.706 to 0.762 in the 7th edition vs. c-index=0.740; 95% CI, 0.712 to 0.768 in the 8th edition; p=0.14), but also in overall survival (c-index=0.717; 95% CI, 0.688 to 0.745 in the 7th edition vs. c-index=0.722; 95% CI, 0.694 to 0.751 in the 8th edition; p=0.19), especially in stage III. This finding was repeated in the subgroup analysis regardless of adjuvant CA or CCRT.
Conclusion
Generally, the 8th edition of AJCC staging system had failed to show a superior discriminatory ability for curatively D2 resected GC patients than the 7th edition, although there was a trend of better prognostic performance of the new edition, regardless of adjuvant treatment method.
Citations
Citations to this article as recorded by
An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study Chao Cai, Cheng Chen, Xiuli Lin, Huihui Zhang, Mingming Shi, Xiaolei Chen, Weisheng Chen, Didi Chen Cancer Medicine.2024;[Epub] CrossRef
Revolutionizing T3-4N0-2M0 gastric cancer staging with an innovative pathologic N classification system Kailai Yin, Xuanhong Jin, Yang Pan, Mengli Zi, Yingsong Zheng, Yubo Ma, Chuhong Pang, Kang liu, Jinxia Chen, Yizhou Wei, Dujiang Liu, Xiangdong Cheng, Li Yuan Journal of Gastrointestinal Surgery.2024; 28(8): 1283. CrossRef
A Comprehensive Review of Prognostic Factors in Patients with Gastric Adenocarcinoma Styliani Mantziari, Penelope St Amour, Francesco Abboretti, Hugo Teixeira-Farinha, Sergio Gaspar Figueiredo, Caroline Gronnier, Dimitrios Schizas, Nicolas Demartines, Markus Schäfer Cancers.2023; 15(5): 1628. CrossRef
Normalization weighted combination scores re-evaluate TNM staging of gastric cancer: a retrospective cohort study based on a multicenter database Junpeng Wu, Hao Wang, Xin Yin, Yufei Wang, Zhanfei Lu, Jiaqi Zhang, Yao Zhang, Yingwei Xue International Journal of Surgery.2023;[Epub] CrossRef
A Substage Increase in The AJCC Classification System Improves Prognostic Prediction in Stage III Gastric Cancer With Insufficient Lymph Nodes Removed Ri-Sheng Zhao, Yi-Nan Liu, Wei-Gang Dai, Si-Le Chen, Jin-Ning Ye, Er-Tao Zhai, Shi-Rong Cai, Jian-Hui Chen Frontiers in Oncology.2021;[Epub] CrossRef
Current therapeutic options for gastric adenocarcinoma C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer Jeong Il Yu, Hee Chul Park, Jeeyun Lee, Changhoon Choi, Won Ki Kang, Se Hoon Park, Seung Tae Kim, Tae Sung Sohn, Jun Ho Lee, Ji Yeong An, Min Gew Choi, Jae Moon Bae, Kyoung-Mee Kim, Heewon Han, Kyunga Kim, Sung Kim, Do Hoon Lim Cancers.2020; 12(4): 943. CrossRef
Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, Ki Hyeong Lee, Keon Uk Park, Ki Hwan Kim, Eun Kyung Cho, Yoon Hee Choi, Hye Ryun Kim, Hoon-Gu Kim, Heui June Ahn, Ha Yeon Lee, Hwan Jung Yun, Jin-Hyoung Kang, Jaeheon Jeong, Moon Young Choi, Sin-Ho Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat. 2019;51(2):718-726. Published online September 3, 2018
Purpose
The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI).
Materials and Methods
We conducted a multi-center randomized phase II trial to compare the clinical outcomes between pemetrexed plus cisplatin combination therapy followed by maintenance pemetrexed (PC) and pemetrexed monotherapy (P) after failure of first-line EGFR-TKI. The primary objective was progression-free survival (PFS), and secondary objectives included overall response rate (ORR), overall survival (OS), health-related quality of life (HRQOL), and safety and toxicity profiles.
Results
A total of 96 patientswere randomized, and 91 patientswere treated at 14 centers in Korea. The ORR was 34.8% (16/46) for the PC arm and 17.8% (8/45) for the P arm (p=0.066). With 23.4 months of follow-up, the median PFS was 5.4 months in the PC arm and 6.4 months in the P arm (p=0.114). The median OS was 17.9 months and 15.7 months in PC and P arms, respectively (p=0.787). Adverse events ≥ grade 3 were reported in 12 patients (26.1%) in the PC arm and nine patients (20.0%) in the P arm (p=0.491). The overall time trends of HRQOL were not significantly different between the two arms.
Conclusion
The outcomes of pemetrexed therapy in NSCLC patients with disease progression after firstline EGFR-TKI might not be improved by adding cisplatin.
Citations
Citations to this article as recorded by
The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yu Cancer Research and Treatment.2025; 57(1): 39. CrossRef
Osimertinib with Chemotherapy in
EGFR
-Mutated NSCLC
New England Journal of Medicine.2024; 390(5): 478. CrossRef
Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors Balazs Halmos, Pragya Rai, Jae Min, Xiaohan Hu, Diana Chirovsky, Mark Shamoun, Bin Zhao Frontiers in Oncology.2024;[Epub] CrossRef
Clinical efficacy and safety of pemetrexed with or without either Bevacizumab or Pembrolizumab in patients with metastatic nonsquamous non–small cell carcinoma Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 87. CrossRef
Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment Cheng-Yu Chang, Chung-Yu Chen, Shih-Chieh Chang, Ching-Yi Chen, Yi-Chun Lai, Chun-Fu Chang, Yu-Feng Wei Frontiers in Oncology.2023;[Epub] CrossRef
Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class Joseph N. Samuel, Christopher M. Booth, Elizabeth Eisenhauer, Michael Brundage, Scott R. Berry, Bishal Gyawali JAMA Oncology.2022; 8(6): 879. CrossRef
Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review) Ruizhu Sun, Zhansheng Hou, Yankui Zhang, Bo Jiang Oncology Letters.2022;[Epub] CrossRef
Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam Lung Cancer.2021; 152: 15. CrossRef
Exploring the role of epidermal growth factor receptor variant III in meningeal tumors Rashmi Rana, Vaishnavi Rathi, Kirti Chauhan, Kriti Jain, Satnam Singh Chhabra, Rajesh Acharya, Samir Kumar Kalra, Anshul Gupta, Sunila Jain, Nirmal Kumar Ganguly, Dharmendra Kumar Yadav, Timir Tripathi PLOS ONE.2021; 16(9): e0255133. CrossRef
Risk factors of nephrotoxicity of maintenance pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung Wang Chun Kwok, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam Lung Cancer.2021; 162: 169. CrossRef
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife Current Oncology.2021; 28(6): 4894. CrossRef
Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma Wang Chun Kwok, David Chi Leung Lam, Ka Yan Chiang, James Chung Man Ho, Mary Sau Man Ip, Terence Chi Chun Tam Journal of Chemotherapy.2020; 32(8): 429. CrossRef
Ki Sun Jung, Su Jin Lee, Se Hoon Park, Jae-Lyun Lee, Se-Hoon Lee, Jae Yun Lim, Jung Hun Kang, Suee Lee, Sun Young Rha, Kyung Hee Lee, Ho Young Kim, Ho Yeong Lim
Cancer Res Treat. 2018;50(2):488-494. Published online May 22, 2017
Purpose
The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not been analyzed. We therefore designed a single-arm, open-label, phase II study to determine the efficacy and safety of pazopanib in patients with nccRCC.
Materials and Methods
Patientswith locally advanced or metastatic nccRCC, exceptfor collecting duct or sarcomatoid type, received 800 mg/day of pazopanib daily until progression of disease or intolerable toxicity. One cyclewas defined as 4weeks and tumorresponsewas evaluated every two cycles. The primary objective was overall response rate (ORR).
Results
A total of 29 eligible patients were enrolled at nine centers in Korea from December 2012 and September 2014. The median age of the patients was 58 years (range, 27 to 76 years) and 21 patients (72%) were male. Regarding histology type, 19 patients had papillary, three had chromophobe, two had unclassified and five had unknown non-clear cell type. Of 28 evaluable patients, eight achieved a confirmed partial response with ORR of 28%. The median progression-free survival was 16.5 months (95% confidence interval, 10.9 to 22.1) and median overall survival was not reached. Sixteen patients (55%) experienced treatment-related toxicity of grade 3 or more, but most adverse events were overcome through dose reduction and delay.
Conclusion
In this prospective phase II study, pazopanib demonstrated promising activity and tolerable safety profile in patients with metastatic nccRCC.
Citations
Citations to this article as recorded by
Systemic therapy for non–clear cell renal cell carcinomas: A systematic review Balqees Ara, Anum Babar, Durkho Atif, Bushra Ghafoor, Mustafa Shah, Syed Maaz Abdullah, Danish Safi, Amir Kamran Journal of Oncology Pharmacy Practice.2025; 31(1): 128. CrossRef
Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov International Journal of Cancer.2024; 154(6): 947. CrossRef
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves e Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P. Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andra Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Papillary Renal Cell Carcinoma: Current Evidence and Future Directions Albert Jang, Charbel S. Hobeika, Shilpa Gupta Kidney Cancer.2024; 8(1): 61. CrossRef
Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma Hasan Cagri Yildirim, Ertuğrul Bayram, Elvin Chalabiyev, Nargız Majidova, Tugay Avci, Halil Göksel Güzel, Caner Kapar, Mehmet Uzun, Perihan Perkin, Fahri Akgül, Saadet Sim Yildirim, Seda Sali, Anil Yildiz, Seher Nazli Kazaz, Engin Hendem, Murat Arcagok, G Journal of Chemotherapy.2024; : 1. CrossRef
Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective Gaetano Pezzicoli, Vittoria Musci, Federica Ciciriello, Francesco Salonne, Paola Cafforio, Nicoletta Lionetti, Anna Ragno, Mimma Rizzo Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis Yaping Zhang, Jian Chen, Xiaoyan Wang, Hui Wang, Xiaoli Chen, Jianfeng Hong, Hongming Fang Frontiers in Oncology.2024;[Epub] CrossRef
Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma Floriane Izarn, Benoît Allignet, Romane Gille, Helen Boyle, Eve-Marie Neidhardt, Sylvie Négrier, Aude Fléchon Clinical Genitourinary Cancer.2023; 21(2): e35. CrossRef
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022) María José Méndez-Vidal, Martin Lázaro Quintela, Nuria Lainez-Milagro, Begoña Perez-Valderrama, Cristina Suárez Rodriguez, José Ángel Arranz Arija, Ignacio Peláez Fernández, Enrique Gallardo Díaz, Julio Lambea Sorrosal, Aránzazu González-del-Alba Clinical and Translational Oncology.2023; 25(9): 2732. CrossRef
Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium Cihan Erol, Emre Yekedüz, Deniz Tural, Serdar Karakaya, Nihan Şentürk Öztaş, Gökhan Uçar, Saadettin Kılıçkap, İsmail Ertürk, Özlem Nuray Sever, Çağatay Arslan, Ahmet Küçükarda, Orçun Can, Özlem Balvan, Satı Coşkun Yazgan, Mustafa Özgüroğlu, Berna Öksüzoğl Urologia Internationalis.2023; 107(6): 595. CrossRef
The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non‐clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database Tomoyuki Koguchi, Sei Naito, Shingo Hatakeyama, Kazuyuki Numakura, Yumina Muto, Renpei Kato, Takahiro Kojima, Yoshihide Kawasaki, Kento Morozumi, Shuya Kandori, Sadafumi Kawamura, Hiroyuki Nishiyama, Akihiro Ito, Tomonori Habuchi, Wataru Obara, Chikara Oh Cancer Medicine.2023; 12(22): 20677. CrossRef
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Michael Baine, Kathryn Beckermann, Maria I. Carlo, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Arpita Desai, Yasser Ged, Saby George, John L. Gore, Naomi Haas, Steven L. Hancock, Pay Journal of the National Comprehensive Cancer Network.2022; 20(1): 71. CrossRef
Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma Jason R. Brown, Adam Calaway, Erik Castle, Jorge Garcia, Pedro C. Barata Kidney Cancer.2022; 6(1): 53. CrossRef
Non-Clear Cell Renal Cell Carcinoma: Molecular Pathogenesis, Innovative Modeling, and Targeted Therapeutic Approaches Niloofar Khoshdel Rad, Maryam Vahidyeganeh, Mahsa Mohammadi, Anastasia Shpichka, Peter Timashev, Nikoo Hossein-Khannazer, Massoud Vosough International Journal of Translational Medicine.2022; 2(4): 555. CrossRef
Systemic Therapies for the Management of Non–Clear Cell Renal Cell Carcinoma: What Works, What Doesn’t, and What the Future Holds Panagiotis Zoumpourlis, Giannicola Genovese, Nizar M. Tannir, Pavlos Msaouel Clinical Genitourinary Cancer.2021; 19(2): 103. CrossRef
Comprehensive review of chromophobe renal cell carcinoma Rohan Garje, Dean Elhag, Hesham A Yasin, Luna Acharya, Daniel Vaena, Laila Dahmoush Critical Reviews in Oncology/Hematology.2021; 160: 103287. CrossRef
A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma Chelsea K. Osterman, Tracy L. Rose Kidney Cancer.2020; 4(1): 15. CrossRef
Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report Ivana Puliafito, Alessio Russo, Dorotea Sciacca, Caterina Puglisi, Dario Giuffrida Journal of Medical Case Reports.2020;[Epub] CrossRef
On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier American Society of Clinical Oncology Educational Book.2020; (40): 418. CrossRef
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review Melissa Bersanelli, Matteo Brunelli, Letizia Gnetti, Umberto Maestroni, Sebastiano Buti Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Management of Metastatic Renal Cell Carcinoma with Variant Histologies Ronan Flippot, Vijay Damarla, Bradley A. McGregor Urologic Clinics of North America.2020; 47(3): 319. CrossRef
Discovery of Pyrido[3′,2′:5,6]thiopyrano[4,3-d]pyrimidine-Based Antiproliferative Multikinase Inhibitors Silvia Salerno, Elisabetta Barresi, Aída Nelly García-Argáez, Sabrina Taliani, Francesca Simorini, Giorgio Amendola, Stefano Tomassi, Sandro Cosconati, Ettore Novellino, Federico Da Settimo, Anna Maria Marini, Lisa Dalla Via ACS Medicinal Chemistry Letters.2019; 10(4): 457. CrossRef
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study Nieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, Hannah Dzimitrowicz, Jarred Burkart, Daniel M Geynisman, Archana Balakrishnan, I Alex Bowman, Rohit Jain, Walter Stadler, Yousef Zakharia, Vivek Narayan, Benoit Beuselinck, Rana R McKay, Abhishek Tri The Lancet Oncology.2019; 20(4): 581. CrossRef
Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas Keiichi Ito International Journal of Urology.2019; 26(9): 868. CrossRef
Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures Inkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong, Jae Lyun Lee BMC Urology.2019;[Epub] CrossRef
Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha Cancer Research and Treatment.2019; 51(4): 1578. CrossRef
The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review Gregory T. Sneed, Sukdong Lee, Jamie N. Brown, Julia M. Hammond Clinical Genitourinary Cancer.2019; 17(6): 419. CrossRef
A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non–clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus Inkeun Park, Se Hoon Lee, Jae Lyun Lee Clinical Genitourinary Cancer.2018; 16(5): e997. CrossRef
Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan Keiichi Ito, Shuji Mikami, Katsunori Tatsugami, Naoya Masumori, Nobuo Shinohara, Tsunenori Kondo, Shotaro Nakanishi, Yoji Nagashima, Masatoshi Eto, Tomomi Kamba, Naoto Kuroda, Yoshihiko Tomita, Hideyasu Matsuyama, Tetsuro Onishi, Tomoyasu Tsushima, Hayaka Clinical Genitourinary Cancer.2018; 16(6): e1201. CrossRef
Purpose
The aim of this study was to confirm the efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors (GISTs) reported in the GRID phase III trial in Korean patients.
Materials and Methods
Fifty-seven Korean patientswith advanced GISTwho experienced both imatinib and sunitinib failure were enrolled in the management access program between December 2012 and November 2013 and treated with regorafenib (160 mg orally once daily in a 3 weeks on /1 week off).
Results
None of the patients achieved a complete or partial response while 25 patients (44%) showed stable disease for ≥ 12 weeks. With a median follow-up of 12.7 months (range, 0.2 to 27.6 months), the median progression-free survival and overall survival were 4.5 months (95% confidence interval [CI], 3.8 to 5.3) and 12.9 months (95% CI, 8.1 to 17.7), respectively. Interestingly, 15 patients (26%) experienced an exacerbation of their cancer-related symptoms (abdominal pain in eight and abdominal distension in five) during the rest period for regorafenib, but all were ameliorated upon the resumption of regorafenib. The most common grade 3 or 4 adverse event was a hand-foot skin reaction (25%). The regorafenib dose was reduced in 44 patients (77%) due to toxicity, which manifested mainly as a handfoot skin reaction (n=31).
Conclusion
This study confirmed the efficacy and safety of regorafenib for advanced GIST after imatinib and sunitinib failure in Korean patients. Considering the exacerbation of the cancer-related symptoms observed during the rest periods, further exploration of the continuous dosing schedule of regorafenib is warranted in future clinical trials.
Citations
Citations to this article as recorded by
English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Tak International Journal of Clinical Oncology.2024; 29(6): 647. CrossRef
A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours Hyung-Don Kim, Changhoon Yoo, Min-Hee Ryu, Yoon-Koo Kang British Journal of Cancer.2023; 129(2): 275. CrossRef
Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule Maria Susanna Grimaudo, Alice Laffi, Nicolò Gennaro, Roberta Fazio, Federico D’Orazio, Laura Samà, Licia Vanessa Siracusano, Federico Sicoli, Salvatore Lorenzo Renne, Armando Santoro, Alexia Francesca Bertuzzi Frontiers in Oncology.2023;[Epub] CrossRef
Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours Marin Golčić, Robin L. Jones, Paul Huang, Andrea Napolitano Cancers.2023; 15(16): 4081. CrossRef
Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review Charlotte Margareta Brinch, Ninna Aggerholm-Pedersen, Estrid Hogdall, Anders Krarup-Hansen Critical Reviews in Oncology/Hematology.2022; 172: 103650. CrossRef
Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature Deborah van de Wal, Mai Elie, Axel Le Cesne, Elena Fumagalli, Dide den Hollander, Robin L. Jones, Gloria Marquina, Neeltje Steeghs, Winette T. A. van der Graaf, Olga Husson Cancers.2022; 14(7): 1832. CrossRef
Efficacy and safety of regorafenib in Japanese patients with advanced gastrointestinal stromal tumors Ryugo Teranishi, Tsuyoshi Takahashi, Toshirou Nishida, Seiichi Hirota, Yukinori Kurokawa, Takuro Saito, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Masaaki Motoori, Takeshi Omori, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki International Journal of Clinical Oncology.2022; 27(7): 1164. CrossRef
The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review Vahe Khachatryan, Asmaa Muazzam, Chandani Hamal, Lakshmi Sai Deepak Reddy Velugoti, Godfrey Tabowei, Greeshma N Gaddipati, Maria Mukhtar, Mohammed J Alzubaidee, Raga Sruthi Dwarampudi, Sheena Mathew, Sumahitha Bichenapally, Lubna Mohammed Cureus.2022;[Epub] CrossRef
CT Image Examination Based on Virtual Reality Analysis in Clinical Diagnosis of Gastrointestinal Stromal Tumors Zhiying Wang, Qiaoyan Qu, Ke Cai, Ting Xu, Zhihan Lv Journal of Healthcare Engineering.2021; 2021: 1. CrossRef
The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology—When and Why? Agnieszka Kaczmarska, Patrycja Śliwa, Monika Lejman, Joanna Zawitkowska International Journal of Molecular Sciences.2021; 22(21): 12089. CrossRef
Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors Seketoulie Keretsu, Suparna Ghosh, Seung Joo Cho International Journal of Molecular Sciences.2020; 21(21): 8232. CrossRef
Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study Chia‑Hsiang Hu, Chun‑Nan Yeh, Jen‑Shi Chen, Chun‑Yi Tsai, Shang‑Yu Wang, Chi‑Tung Cheng, Ta‑Sen Yeh Oncology Letters.2020; 20(3): 2131. CrossRef
Meta-Analysis of Regorafenib-Associated Adverse Events and Their Management in Colorectal and Gastrointestinal Stromal Cancers Ganfeng Xie, Yuzhu Gong, Shuang Wu, Chong Li, Songtao Yu, Zhe Wang, Jianfang Chen, Quanfeng Zhao, Jianjun Li, Houjie Liang Advances in Therapy.2019; 36(8): 1986. CrossRef
Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib Jae-Joon Kim, Min-Hee Ryu, Changhoon Yoo, Mo Youl Beck, Jung Eun Ma, Yoon-Koo Kang The Oncologist.2019; 24(11): e1212. CrossRef
Growing Role of Regorafenib in the Treatment of Patients with Sarcoma Mark Agulnik, Steven Attia Targeted Oncology.2018; 13(4): 417. CrossRef
Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients Gustavo Schvartsman, Michael J. Wagner, Behrang Amini, Chrystia M. Zobniw, Van Anh Trinh, Andrea G. Barbo, Heather Y. Lin, Wei-Lien Wang, Anthony Paul Conley, Vinod Ravi, Dejka M. Araujo, Maria Alejandra Zarzour, Robert S. Benjamin, Shreyaskumar Patel, Ne Scientific Reports.2017;[Epub] CrossRef
Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib Bin Zhao, Hong Zhao Oncotarget.2017; 8(55): 93813. CrossRef
Su Jin Lee, Silvia Park, Hee Kyung Ahn, Jun Ho Yi, Eun Yoon Cho, Jong Mu Sun, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im
Cancer Res Treat. 2011;43(2):89-95. Published online June 30, 2011
PURPOSE The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis. MATERIALS AND METHODS Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases. RESULTS The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077). CONCLUSION Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'
Citations
Citations to this article as recorded by
Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis Nour Arakil, Shahid Akhtar Akhund, Basant Elaasser, Khalid S. Mohammad Biomedicines.2024; 12(5): 1075. CrossRef
Germacrone alleviates breast cancer‐associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF‐κB signaling pathways Zhengjun Lin, Yaocheng Yang, Tang Liu, Ziyi Wu, Xianghong Zhang, Jing Yang Phytotherapy Research.2024; 38(6): 2860. CrossRef
Acro metastasis: A rare presentation in a common cancer Ali Ghanei-Shahmirzadi, Nasrin Namdari, Maral Mokhtari, Pooya Iranpour Current Problems in Cancer: Case Reports.2024; 14: 100292. CrossRef
Concise review: breast cancer stems cells and their role in metastases Mohammad Kamalabadi Farahani, Mohammad Farjadmehr, Amir Atashi, Alireza Momeni, Mahin Behzadifard Annals of Medicine & Surgery.2024;[Epub] CrossRef
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels Saptarshi Sinha, Brennan W. Callow, Alex P. Farfel, Suchismita Roy, Siyi Chen, Maria Masotti, Shrila Rajendran, Johanna M. Buschhaus, Celia R. Espinoza, Kathryn E. Luker, Pradipta Ghosh, Gary D. Luker Journal of Clinical Investigation.2024;[Epub] CrossRef
Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion Dominique Leblanc, Guy Cantin, Alexandra Desnoyers, Jean Dufresne, Giuseppina Laura Masucci, Valérie Panet-Raymond, Éric Poirier, Sara Soldera, Isabelle Gingras Current Oncology.2023; 30(2): 1416. CrossRef
Surgery in the Setting of Metastatic Breast Cancer Jennifer K. Plichta, Mahsa Taskindoust, Rachel A. Greenup Current Breast Cancer Reports.2023; 15(1): 37. CrossRef
Team Approach: Management of Pathologic Fractures Aws Hammad, Osman Ahmed, Philip P. Connell, Daniel Olson, Tessa Balach JBJS Reviews.2023;[Epub] CrossRef
Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study Gianluca Bottoni, Francesco Fiz, Matteo Puntoni, Federica Matteucci, Manuela Monti, Andrea DeCensi, Oriana Nanni, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gianmauro Sacchetti, Pierpaolo Trimboli, Giorgio Treglia, Nadia Harbeck, Simona Sola, Alessan European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(8): 2477. CrossRef
Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort Alexandre Prieur, Andrew Harper, Momtafin Khan, Bérengère Vire, Dominique Joubert, Léa Payen, Karen Kopciuk BMC Cancer.2023;[Epub] CrossRef
SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches Qiuyao Wu, Pu Tian, Dasa He, Zhenchang Jia, Yunfei He, Wenqian Luo, Xianzhe Lv, Yuan Wang, Peiyuan Zhang, Yajun Liang, Wenjin Zhao, Jun Qin, Peng Su, Yi-Zhou Jiang, Zhi-Ming Shao, Qifeng Yang, Guohong Hu Cell Research.2023; 33(6): 464. CrossRef
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer Mónica Cejuela, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, Javier Salvador Bofill International Journal of Molecular Sciences.2023; 24(10): 8488. CrossRef
Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer Kang Yao, Zhu Xiaojun, Zhao Tingxiao, Liao Shiyao, Ji Lichen, Zhang Wei, Li Yanlei, Tian Jinlong, Ding Xiaoyan, Zhang Jun, Bi Qing, Lv Jun BMC Cancer.2023;[Epub] CrossRef
Diagnostic and Prognostic Role of 18F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept Francesco Fiz, Gianluca Bottoni, Giorgio Treglia, Pierpaolo Trimboli, Arnoldo Piccardo Journal of Clinical Medicine.2022; 11(13): 3589. CrossRef
Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient’s Prognosis Cheng-cheng Yu, Yi-nan Wu, Kai-min Hu, Su-zhan Zhang, Ali Imran BioMed Research International.2022;[Epub] CrossRef
Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis Wucheng Wen, Pengbo Guo, Hui Yi Xue, Ho Lun Wong International Journal of Pharmaceutics.2022; 625: 122092. CrossRef
Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer Lina Marie, Dina Braik, Nayef Abdel-Razeq, Hala Abu-Fares, Ahmad Al-Thunaibat, Hikmat Abdel-Razeq Cancer Management and Research.2022; Volume 14: 2519. CrossRef
Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies Lulian Pang, Chen Gan, Jian Xu, Yingxue Jia, Jiaying Chai, Runze Huang, Anlong Li, Han Ge, Sheng Yu, Huaidong Cheng Cancers.2022; 14(23): 5727. CrossRef
Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies? E. Pons-Tostivint, E. Alouani, Y. Kirova, F. Dalenc, C. Vaysse Critical Reviews in Oncology/Hematology.2021; 157: 103146. CrossRef
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim European Journal of Cancer.2021; 144: 341. CrossRef
Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone Shuzhong Liu, An Song, Yunxiao Wu, Siyuan Yao, Muchuan Wang, Tong Niu, Chengao Gao, Ziquan Li, Xi Zhou, Zhen Huo, Bo Yang, Yong Liu, Yipeng Wang Translational Oncology.2021; 14(2): 100993. CrossRef
Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis Chiara Spadazzi, Laura Mercatali, Mark Esposito, Yong Wei, Chiara Liverani, Alessandro De Vita, Giacomo Miserocchi, Elisa Carretta, Michele Zanoni, Claudia Cocchi, Alberto Bongiovanni, Federica Recine, Yibin Kang, Toni Ibrahim Bone.2021; 144: 115775. CrossRef
Diagnosis and referral of adults with suspected bony metastases Samantha Downie, Elizabeth Bryden, Fergus Perks, A Hamish RW Simpson BMJ.2021; : n98. CrossRef
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos Cancers.2021; 13(6): 1458. CrossRef
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT Gianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, Giacomo Siri, Federica Matteucci, Andrea Rocca, Oriana Nanni, Manuela Monti, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gian Mauro Sacchetti, Chiara Saggia, Valentina Rossi, Nadia Harbeck, Rachel Wue European Journal of Radiology.2021; 141: 109821. CrossRef
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis Daniel Reinhorn, Raz Mutai, Rinat Yerushalmi, Assaf Moore, Eitan Amir, Hadar Goldvaser The Breast.2021; 58: 173. CrossRef
Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi Nature Communications.2021;[Epub] CrossRef
Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening? Adam S. Komorowski, Ellen Warner, Helen J. MacKay, Arjun Sahgal, Kathleen I. Pritchard, Katarzyna J. Jerzak Clinical Breast Cancer.2020; 20(1): e54. CrossRef
Radiation therapy for bone-only metastases in breast cancer patients: A GOCO survey of current clinical practice Marta Bonet, Virginia García, Núria Farré, Manel Algara, Blanca Farrús, Jaume Fernandez, Victoria Reyes, Arancha Eraso, Ana Álvarez, Maria José Cambra, Agustí Pedro, Jordi Vayreda, Claire Lemansky, Françoise Izar, Meritxell Arenas Reports of Practical Oncology & Radiotherapy.2020; 25(1): 113. CrossRef
MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9 Xinxin Zhang, Xiying Yu, Zhenguo Zhao, Zhennan Yuan, Peiqing Ma, Zhibin Ye, Liping Guo, Songfeng Xu, Libin Xu, Ting Liu, Huanmei Liu, Shengji Yu Bone.2020; 130: 115139. CrossRef
Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival Najla Itani, Nicole Grogan, Sarah Mott, Sneha Phadke Clinical Breast Cancer.2020; 20(3): 209. CrossRef
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer Cynthia Huang Bartlett, Jack Mardekian, Matthew James Cotter, Xin Huang, Zhe Zhang, Christina M. Parrinello, Ariel Bulua Bourla, Apar Kishor Ganti PLOS ONE.2020; 15(4): e0227256. CrossRef
International Framework for Red Flags for Potential Serious Spinal Pathologies Laura M. Finucane, Aron Downie, Christopher Mercer, Susan M. Greenhalgh, William G. Boissonnault, Annelies L. Pool-Goudzwaard, Jason M. Beneciuk, Rachel L. Leech, James Selfe Journal of Orthopaedic & Sports Physical Therapy.2020; 50(7): 350. CrossRef
Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer Liang Jin, Kai Chen, Cui Tan, Jianbin Li, Jiayue Luo, Yaping Yang, Yudong Li, Shunying Li, Liling Zhu, Yue Hu, Fengtao Liu, Qiuting You, Min Peng, Zefei Jiang, Qiang Liu The Oncologist.2020; 25(8): e1170. CrossRef
Imaging diagnosis of metastatic breast cancer Filippo Pesapane, Kate Downey, Anna Rotili, Enrico Cassano, Dow-Mu Koh Insights into Imaging.2020;[Epub] CrossRef
Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells Yung-Chieh Chang, Chun Hei Antonio Cheung, Yao-Lung Kuo Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials Richard S. Finn, Massimo Cristofanilli, Johannes Ettl, Karen A. Gelmon, Marco Colleoni, Carla Giorgetti, Eric Gauthier, Yuan Liu, Dongrui R. Lu, Zhe Zhang, Cynthia Huang Bartlett, Dennis J. Slamon, Nicholas C. Turner, Hope S. Rugo Breast Cancer Research and Treatment.2020; 184(1): 23. CrossRef
Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons Ania Naila Guerrieri, Monica Montesi, Simone Sprio, Roberta Laranga, Laura Mercatali, Anna Tampieri, Davide Maria Donati, Enrico Lucarelli Frontiers in Bioengineering and Biotechnology.2020;[Epub] CrossRef
The influence of breast cancer subtype on survival after palliative radiation for osseous metastases Mohamed K. Abdelhakiem, Candice Johnstone, Carmen Bergom, Adam Currey, Jared R. Robbins Cancer Medicine.2020; 9(23): 8979. CrossRef
Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics Jin-Xiao Ren, Yue Gong, Hong Ling, Xin Hu, Zhi-Ming Shao Breast Cancer Research and Treatment.2019; 173(1): 225. CrossRef
Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study Kang Wang, Yang Shi, Zhu-Yue Li, Ye-Lei Xiao, Jie Li, Xiang Zhang, Hong-Yuan Li European Journal of Surgical Oncology.2019; 45(8): 1364. CrossRef
The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis Ricardo Romero-Moreno, Kimberly J. Curtis, Thomas R. Coughlin, Maria Cristina Miranda-Vergara, Shourik Dutta, Aishwarya Natarajan, Beth A. Facchine, Kristen M. Jackson, Lukas Nystrom, Jun Li, William Kaliney, Glen L. Niebur, Laurie E. Littlepage Nature Communications.2019;[Epub] CrossRef
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study Guenther G. Steger, Adriana Dominguez, Natalia Dobrovolskaya, Francesco Giotta, Nicole Tubiana-Mathieu, Martin Pecherstorfer, Antonio Ardizzoia, Maria Blasinska-Morawiec, Enrique Espinosa, Gustavo Villanova Clinical Breast Cancer.2018; 18(1): e41. CrossRef
Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010 Judith A. Malmgren, Musa Mayer, Mary K. Atwood, Henry G. Kaplan Breast Cancer Research and Treatment.2018; 167(2): 579. CrossRef
Breast cancer bone metastases: pathogenesis and therapeutic targets Naomi Brook, Emily Brook, Arun Dharmarajan, Crispin R. Dass, Arlene Chan The International Journal of Biochemistry & Cell Biology.2018; 96: 63. CrossRef
Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data Hongwei Zhang, Wei Zhu, Ewelina Biskup, Weige Yang, Ziang Yang, Hong Wang, Xiaochun Qiu, Chengjiao Zhang, Guangxia Hu, Guangfu Hu Journal of Bone Oncology.2018; 11: 38. CrossRef
Breast osteoblast-like cells: a new biomarker for the management of breast cancer Manuel Scimeca, Nicoletta Urbano, Rita Bonfiglio, Orazio Schillaci, Elena Bonanno British Journal of Cancer.2018; 119(9): 1129. CrossRef
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita Breast Cancer.2017; 24(3): 473. CrossRef
Pattern of metastatic spread and subcategories of breast cancer Catharina Bartmann, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Joachim Diessner Archives of Gynecology and Obstetrics.2017; 295(1): 211. CrossRef
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid Claudia Omarini, Maria E. Filieri, Roberta Depenni, Giulia Grizzi, Stefano Cascinu, Federico Piacentini The Breast Journal.2017; 23(5): 610. CrossRef
The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone Aurélie Bellanger, Caterina F Donini, Julie A Vendrell, Jonathan Lavaud, Irma Machuca‐Gayet, Maëva Ruel, Julien Vollaire, Evelyne Grisard, Balázs Győrffy, Ivan Bièche, Olivier Peyruchaud, Jean‐Luc Coll, Isabelle Treilleux, Véronique Maguer‐Satta, Véroniqu The Journal of Pathology.2017; 242(1): 73. CrossRef
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis I Bado, Z Gugala, S A W Fuqua, X H-F Zhang Oncogene.2017; 36(32): 4527. CrossRef
Which red flags aid the early detection of metastatic bone disease in back pain? Laura Finucane, Susan Greenhalgh, James Selfe Physiotherapy Practice and Research.2017; 38(2): 73. CrossRef
Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis Soyeon Park, Joon-Kee Yoon, Su Jin Lee, Seok Yun Kang, Hyunee Yim, Young-Sil An Medicine.2017; 96(50): e8985. CrossRef
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Shinji Ohno Clinical Breast Cancer.2016; 16(4): 238. CrossRef
Quality of life and symptom burden in patients with metastatic breast cancer Christine Ecclestone, Ronald Chow, Natalie Pulenzas, Liying Zhang, Angela Leahey, Julia Hamer, Carlo DeAngelis, Gillian Bedard, Rachel McDonald, Anchal Bhatia, Janet Ellis, Eileen Rakovitch, Sherlyn Vuong, Edward Chow, Sunil Verma Supportive Care in Cancer.2016; 24(9): 4035. CrossRef
Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer Joachim Diessner, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Catharina Bartmann BMC Cancer.2016;[Epub] CrossRef
Prolactin receptor in breast cancer: marker for metastatic risk Carrie S Shemanko Journal of Molecular Endocrinology.2016; 57(4): R153. CrossRef
Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers Megumi Kai, Takahiro Kogawa, Diane D. Liu, Tamer M. Fouad, Kazuharu Kai, Naoki Niikura, Limin Hsu, Jie S. Willey, Richard L. Theriault, Vicente Valero, Naoto T. Ueno Clinical Breast Cancer.2015; 15(1): 37. CrossRef
Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer Iain R. Macpherson, Caroline Bray, Carol Hopkins, Rosemary A. Hannon, Liz-Anne Lewsley, Diana M. Ritchie, Peter Canney Clinical Breast Cancer.2015; 15(2): 117. CrossRef
Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? D.K. Woolf, A.R. Padhani, A. Makris Annals of Oncology.2015; 26(6): 1048. CrossRef
Survival time according to the year of recurrence and subtype in recurrent breast cancer Masahiro Nakano, Mamiko Fujisue, Rumiko Tashima, Yasuhiro Okumura, Yasuyuki Nishiyama, Tomofumi Ohsako, Yasuo Toyozumi, Nobuyuki Arima, Reiki Nishimura The Breast.2015; 24(5): 588. CrossRef
Cases of Bone-only Metastasis in Recurrent Breast Cancer Yoko MAEKAWA, Shintaro TAKAO, Koichi HIROKAGA, Mayuko MIKI, Sachiko YOSHIDA Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2014; 75(6): 1484. CrossRef
Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors June Koo Lee, Seock-Ah Im, Daewon Lee, Ji-Yeon Kim, Yoojoo Lim, Eunyoung Lee, Hyeong-Gon Moon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh Journal of Breast Cancer.2013; 16(1): 66. CrossRef
Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre I. Kuchuk, B. Hutton, P. Moretto, T. Ng, C.L. Addison, M. Clemons Journal of Bone Oncology.2013; 2(4): 137. CrossRef
Zooming in on the schedule of bone-modifying drugs Miguel Martin, Sara López-Tarruella The Lancet Oncology.2013; 14(7): 575. CrossRef
Bone metastases: assessment, management and treatment options Carole Farrell British Journal of Nursing.2013; 22(Sup7): S4. CrossRef
Limites de la scintigraphie osseuse dans le suivi des métastases osseuses du carcinome mammaire : étude du centre tunisien K. Chatti, A. Harrabi, I. Chabchoub, T. Kamoun, R. Sfar, M. Nouira, M.B. Fredj, N. Ayachi, S.B. Ahmed, H. Essabbah Médecine Nucléaire.2012; 36(10): 574. CrossRef
PURPOSE To ascertain the factors associated with the proportion of death certificate only (DCO) cases contained in the Kwangju Cancer Registry (KCR) that are not as yet in the good range. MATERIALS AND METHODS The distribution of DCO cases was analyzed by sex, age, cancer site, histological verification (HV) as well as the physician's death certificate status. RESULTS All cases (n=4,243) in Kwangju diagnosed as having cancer between 1997 and 1998 were registered with the KCR.
Death certificates (n=2,390) reporting cancer as the causes of death were collected from the National Statistics Office and reviewed with hospital data linkage and a total of 590 cases were registered as DCO. DCOs accounted for 12.2% (male 12.8%, female 11.5%) of all registrations in Kwangju, 1997~1998. The proportion of DCO cases was high in subjects under 15 (male13.5%,female 9.4%) as well as those 75 and over (male 20.3%, female 27.2%). For cancer sites, the proportion of DCO cases was high (over 10%) for liver, bronchus-lung, esophagus and pancreas and low (under 3%) for skin, bladder, uteri cervix and breast. The proportion of DCO cases was inversely associated with HV%. When the death certificate was issued by physician, the possibility of DCO decreased. CONCLUSION The proportion of DCO is positively associated with increasing age and negatively associated with HV% and the issuance of a physician's death certificate. These findings suggest that further socio-cultural efforts are required to reduce the DCO proportion.